KRAS G12C inhibitors mark a breakthrough in oncology, but resistance is driving the need for smarter preclinical models and ...

World Outcomes Of Non-Small Cell Lung Cancer Patients Harbouring Kras G12c And Kras G12d Mutations," published in the March 2025 issue of Lung Cancer by Shahnam et al. KRAS G12D and G12C mutations exh ...

Bottom Line: Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C ...

Vectibix (panitumumab), for treating KRAS G12C-mutated metastatic colorectal cancer (mCRC). The regulatory body approved Lumakras plus Vectibix for treating KRAS G12C-mutated mCRC in adult ...

Amgen’s Lumakras and Bristol Myers Squibb’s Krazati (from Mirati Therapeutics), which address a specific mutation called KRAS ...

BMS is already testing the combo against just Keytruda as a first-line treatment in a Phase III trial in KRAS G12C-mutant and ...

While not statistically significant, the use of sotorasib plus panitumumab may have a 30% relative risk reduction in the risk of death compared to the investigator’s choice of chemotherapy in the ...

Verastem, Inc.'s priority PDUFA date for avutometinib + defactinib in LGSOC set for June 2025; explore future data updates. Click for my VSTM stock update.